VAS Questionnaire
For the evaluation of the effects of high-isoflavone soybeans on skin and hair conditions, joints functions, and bowl movements, the subjects completed a VAS questionnaire. The VAS questionnaire consisted of 12 questions assessing 1) their Skin blotching, 2) Skin dullness, 3) Skin mat, 4) Skin dryness, 5) Skin acne, 6) Hair volume, 7) Hair shine, 8) Knee pain, 9) Knee rigidity, 10) Defecation regularity, 11) Defecation difficulty, and 12) Defecation satisfaction [19, 20] . Subjects were instructed to make a "cross-mark" on a 100-mm line for addressing each question based on their current health condition. The left end of the line (0 mm) was defined as the worst condition and the right end (100 mm) as the best condition. The questionnaire's results were assessed by evaluating the length from the left end to the cross-mark. The increase in the VAS score indicated an improvement for each symptom.
Study Design
The clinical study was conducted as a double-blind, placebo-controlled trial and was operated in Hokkaido Information University, Health Information Science Research Center (Ebetsu city, Hokkaido, Japan). The examination schedule for this study is shown in Table 1 . SMI was performed at weeks 0 (baseline), 4, and 8 after the start of test food ingestion. At all three time points, a medical interview was conducted along with an assessment of vital signs, hematological and biological variables, urinalysis, body composition and visual analog scale (VAS) of skin and hair conditions, joints functions, and bowel movements. To investigate the dose-dependent effects of isoflavone, we asked the subject groups to consume daily (1) 8.5 g of active soybean flakes (high-isoflavone), containing 29.75 mg of isoflavone aglycones (active test food group), (2) placebo soybean flakes (low-isoflavone), containing 8.5 mg of isoflavone aglycones (Placebo 2 food group), or wheat flakes, non-containing of isoflavone aglycones (Placebo 1 food group) at any time of the day. This intake volume of isoflavone was determined in consideration of the food safety intake guidelines set forth by the Food Safety Commission of Japan. During this study, the subjects were asked not to change their daily activities, including food consumption, medication, and exercises. The primary outcomes were SMI scores, urinary type I collagen cross-linked N-telopeptide (NTx), urinary deoxypyridinoline (Dpyr), and serum TRACP-5b. The secondary outcomes were lipid metabolism [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG)]; transferrin [unsaturated iron binding capacity (UIBC) and total iron binding capacity (TIBC)]; VAS score of skin and hair conditions, joints functions, and bowel movements; and body composition [body weight (BW), body mass index (BMI), and body fat percentage (BFP)]. Blood and urinary tests were performed by Sapporo Clinical Laboratory, Inc. (Sapporo, Japan). TRACP-5b was measured using enzyme immunoassay (EIA); transferrin using bathophenanthroline method; hormones using chemiluminescent enzyme immunoassay; FBG and HbA1c using hexokinase method and latex agglutination test respectively; TG, TC, HDL-C, and LDL-C using free glycerol, cholesterol oxidase, selective inhibition, and selective solubilisation methods respectively; WBCs, RBCs, Hb level, Ht and Plt levels using automatic blood cell counting device; FBG and HbA1c using hexokinase method and latex agglutination inhibition assay, respectively; AST, ALT, γ-GTP, ALP, and LDH using Japan Society of Clinical Chemistry (JSCC) reference method; BUN, Cr, and UAC using urease-GLDH method, enzyme assay and uricase-POD method respectively; and urinary NTx and Dpyr using EIA.
Each subject's body composition and BP were measured using a Body Composition
Analyzer DC-320 (Tanita Corp, Tokyo, Japan) and an Automatic Blood Pressure Monitor HEM-7080IC (Omron Co., Ltd., Kyoto, Japan) respectively.
Ethics Committee
All subjects written informed consent prior to undergoing any of the tests related to this study.
The Ethics Committee of Hokkaido Information University approved the study protocol in conformity to the Helsinki Declaration (approval date: Sep 30, 2015, approval number:
2015-15). This study was registered with UMIN (approval number: UMIN000019450).
Sample Size
The sample size was statistically determined to obtain a power of 80% with an alpha of 0.05. To demonstrate an effect on SMI at week 8, which was postulated to be a 5-point reduction with a standard deviation (SD) of 5.00, a sample size of 60 (20 in each group) was required. Assuming a 20% loss in the follow-up rate, 75 subjects were selected. 
Statistical Analysis

RESULTS
Subject Dropouts, Exclusions, and Characteristics
During the trial, four subjects withdrew for personal reasons. Consequently, 71 subjects completed this trial (active test food group, n = 24; Placebo 1 food group, n = 23; Placebo 2 food group, n = 24). Two subjects were excluded from the analysis of the "per protocol set" because of their low ingestion rate (Placebo 2 food group, n = 2). The study flow diagram is shown in Figure 1 . The mean age, height, BW, BMI, BFP, SMI score, and serum TRACP-5b for each group are presented in Table 3 . These data did not differ significantly between the active test and Placebo food groups, confirming the appropriate allocation of subjects into the three groups. 
Effects of High-Isoflavone Soybeans on Menopausal Symptoms
First, we evaluated the effects of high-isoflavone soybeans on menopausal symptom using SMI ( 
Effects of High-Isoflavone Soybean on Bone Metabolism Parameters
We also evaluated the effects of high-isoflavone soybeans on bone metabolism parameters (urinary NTx, urinary Dpyr, and serum TRACP-5b). There were no significant differences between the active test and Placebo 1 food groups and the active test and Placebo 2 food groups regarding changes in urinary NTx, urinary Dpyr, and serum TRACP-5b (Table 5 ). 
Effects of High-Isoflavone Soybeans on VAS Scores
To confirm the effects of high-isoflavone soybeans on skin/hair condition, joint functions and fecal properties, we evaluated changes in VAS based on a questionnaire rating 12 factors (Table   6 ). "Skin dryness" was improved after ingestion of the active test food compared to the Placebo 
Effects of High-Isoflavone Soybeans on Lipid Metabolism Parameters, Transferrin, and Body
Composition
We evaluated lipid metabolism parameters (TC, LDL-C, HDL-C, and TG), transferrin (TIBC and UIBC), and body composition (BW, BFP, and BMI) after the ingestion of the test food (Table 7) . There were no differences between the active test and Placebo 1 food groups and the active test and Placebo 2 food groups regarding changes in all parameters. 
Safety
We evaluated BP, CBCs, glucose metabolism parameters, liver and renal function, and hormone levels after ingestion of the test foods. As shown in Table 8 , minimal changes were observed in BP (SBP and DBP), CBC parameters (WBCs, RBCs, Hb, Ht, and Plt), glucose metabolism parameters (FBG and HbA1c), liver function (AST, ALT, γ-GTP, ALP, and LDH), renal function (BUN, CRE, and UA), hormones (E2, and FSH). Few subjects exhibited adverse effects (gastrointestinal disorders, n=29; insomnia/agitation, n=5; respiratory disorders, n=38; headache, n=28; vertigo, n=5; fever, n=15). These subjects presented only mild symptoms and recovered within a few brief days; therefore, the principal investigator judged that no adverse events were related to the ingestion of the test food. These results suggested that the ingestion of high-isoflavone soybean ("Yukipirika") had no or minimal unfavorable effects even at a dose of 8.5
g/day (dry weight soybeans). 
DISCUSSION
This clinical trial revealed that high-isoflavone soybeans displayed more beneficial effects on menopausal symptom, skin condition, joints functions, and bowel movements compared to low-isoflavone soybean or wheat in climacteric women.
There were no significant differences between the active test and Placebo 1 food groups and the active test and Placebo 2 food groups regarding changes in total scores of SMI.
However, sub-scores from questions 1 to 4 of SMI significantly decreased in the active test group compared to the Placebo 2 group, suggesting an improvement. Questions 1 to 4 assessed the "menopausal symptoms" caused by the reduction in estrogen secretion. The chemical structures of isoflavone are similar to that of estradiol, while compounds of isoflavone appear to exert an estrogenic or anti-estrogenic effect depending on the circulating estrogen levels [10, 21] . Previous clinical studies have reported that 12 weeks of continuous ingestion of 80 mg isoflavone significantly decreased the frequency of hot flashes compared to the ingestion of the placebo food [22] . The levels of E2 and FSH did not change during this clinical study. These facts suggest that the isoflavone contained in the active test food "Yukipirika" did in fact improve "menopausal symptoms".
Urinary NTx, urinary Dpyr, and serum TRACP-5b were not different among the active test food, Placebo 1 food and Placebo 2 food groups in all analyses performed and in each subgroup analysis (pre-/post-menopause). A previous study has shown that 2 weeks of ingesting 25 mg daily of soy isoflavone aglycone significantly decreases Dpyr [23] . However, results of our meta-analysis indicated that the effects of isoflavone intake on osteoporosis are not clear [24] .
We need to re-evaluate our intake period and inclusion criteria considered.
The active test food intake tended to improve the score of "skin mat" in the VAS questionnaire compared to Placebo 2 food intake at week 8. Additionally, the score of "skin dryness" in the VAS questionnaire was increased by the ingestion of the active test food compared to Placebo 2 food at week 4 and week 8. However, "skin acne" was decreased by the ingestion of the active test food compared to Placebo 1 and Placebo 2 food at week 4. The increase of skin acne by the intake of the active test food might be observed as a result of improvement of "skin dryness." Previous clinical trials suggested that a 12-week intake of soybean hypocotyls significantly improved melanin formation caused by aging [20] .
Additionally, soy isoflavone glycitin inhibited skin aging and wrinkles by promoting human dermal fibroblast cell proliferation and migration via transforming growth factor -β [25] . All these reports support our data, showing that the isoflavones contained in the active test food improved skin condition in our clinical study.
The score of "knee pain" in the VAS questionnaire improved in the active test food group compared to the Placebo 1 food group at weeks 4 and 8. Moreover, the intake of the active test food increased "knee rigidity" compared to the Placebo 2 and Placebo 1 food groups at week 4.
Knee osteoarthritis (OA) is a progressive joint disease that serves as one of the primary causes of physical disability with advancing age [26, 27] . The goal of OA treatment is to reduce symptoms and slow disease progression [28] . Natural compounds such as chondroitin and glucosamine are used for OA medicine. It was reported that oxidative stress is related to the progression of OA [29] , while isoflavones display anti-oxidative effects [30, 31] . Moreover, it has been reported that genistein and daidzein suppressed inflammation in animal models of rheumatoid arthritis [32] . This fact suggests that the intake of high-isoflavone soybeans improves OA symptoms via antioxidants and anti-inflammation. Nevertheless, further clinical trials are required to test subjects with knee pain for the effects of high-isoflavone soybeans on OA.
Active test food intake improved the score of "Defecation difficulty" in the VAS questionnaire compared to Placebo 2 food intake at weeks 4 and 8. Additionally, the score of "Defecation satisfaction" was improved by ingestion of the active test food compared to the ingestion of Placebo 2 food at week 8. This fact suggests that the intake of high-isoflavone soybeans improved bowel movement. The isoflavone daidzein is metabolized to equol by intestinal bacteria [33] . However, the research on the effect of isoflavone and its metabolite to intestinal flora was limited. Further clinical trials are required to subjects with constipation for the effects of high-isoflavone soybeans on intestinal flora.
CONCLUSION
The results of this study revealed that high-isoflavone soybeans improved the menopausal symptoms of climacteric women. Furthermore, high-isoflavone soybeans had positive effects on skin conditions, joints functions, and bowel movements. In an aging society like Japan, it is important to research and develop foods that are rich with nutrients and functional components, which can continue to address these problems. Although further clinical trials with long-intake period of high-isoflavone soybean diet are required, the present study promotes the development of new applications of isoflavone-enriched food using the high-isoflavone soybean "Yukipirika". Competing Interests: There are no conflicts of interest to declare.
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